Galmed Pharmaceuticals Ltd.
(NASDAQ : GLMD)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
ICPTIntercept Pharmaceuticals, Inc.
1.86%93.5418.6%$137.04m
AMRNAmarin Corporation Plc Sponsored ADR
11.13%19.372.0%$115.79m
SAGESAGE Therapeutics, Inc.
3.51%151.319.5%$74.40m
JAZZJazz Pharmaceuticals Plc
1.18%126.692.2%$72.83m
PRGOPerrigo Co. Plc
0.63%48.636.8%$61.23m
GWPHGW Pharmaceuticals PLC Sponsored ADR
4.91%151.026.3%$59.56m
CTLTCatalent Inc
1.01%42.972.4%$42.70m
PTLAPortola Pharmaceuticals, Inc.
1.76%30.687.7%$42.35m
ICLRICON Plc
1.86%144.804.1%$35.40m
CORTCorcept Therapeutics Incorporated.
3.07%11.435.5%$30.47m
HZNPHorizon Pharma plc
0.47%21.347.4%$29.77m
UTHRUnited Therapeutics Corporation
0.57%117.6914.4%$29.28m
MDCOMedicines Company
2.55%24.5121.8%$27.84m
AERIAerie Pharmaceuticals, Inc.
1.24%39.186.9%$26.85m
MNKMallinckrodt Plc
3.80%21.3021.1%$25.37m

Company Profile

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It focuses on the development of the liver targeted stearoyl-coenzyme A desaturase-1 modulator Aramchol, novel, once-daily, oral therapy for the treatment of NASH for variable populations, as well as other liver associated disorders. The Aramchol is a synthetic conjugate of cholic acid, or a type of bile acid, and arachidic acid, or a type of saturated fatty acid, both of which, in their non-synthetic forms, are naturally occurring. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.